Table 1 Clinical characteristics of non-small cell lung cancer patients with brain metastases treated with brain RT stratified by EGFR mutation status
Characteristics | Total (N= 43) | EGFR mutation status | P | |
|---|---|---|---|---|
Positive (n= 30) | Negative (n= 13) | |||
Age, years | 0.332 | |||
  Median (range) | 59 (35-83) | |||
  <60 | 22 (51) | 17 (57) | 5 (38) | |
  ≧60 | 21 (49) | 13 (43) | 8 (62) | |
Gender | 0.054 | |||
  Female | 20 (47) | 17 (57) | 3 (23) | |
  Male | 23 (53) | 13 (43) | 10 (77) | |
Smoking history | 0.043 | |||
  Never | 27 (63) | 22 (73) | 5 (38) | |
  Ever | 16 (37) | 8 (27) | 8 (62) | |
ECOG performance status | 1.60±0.88 | 1.60±0.89 | 1.62±0.87 | 0.959 |
RPA class | 1.000 | |||
  Class I | 5 (12) | 4 (13) | 1 (8) | |
  Class II | 31 (72) | 21 (70) | 10 (77) | |
  Class III | 7 (16) | 5 (17) | 2 (15) | |
Primary tumor status | 1.000 | |||
  Controlled | 29 (67) | 20 (67) | 9 (69) | |
  Uncontrolled | 14 (33) | 10 (33) | 4 (31) | |
Extracranial metastases | 1.000 | |||
  Absent | 12 (28) | 8 (27) | 4 (31) | |
  Present | 31 (72) | 22 (73) | 9 (69) | |
Number of BM | 0.491 | |||
  ≦3 | 14 (33) | 11 (37) | 3 (23) | |
  >3 | 29 (67) | 19 (63) | 10 (77) | |
Size of largest BM (mm) | 22.07±10.91 | 24.51±11.74 | 16.45±5.89 | 0.024 |
Hemorrhagic BM | 0.019 | |||
  No | 32 (74) | 19 (63) | 13 (100) | |
  Yes | 11 (26) | 11 (37) | 0 (0) | |
Total dose | 0.310 | |||
  ≦40 Gy2 | 26 (60) | 20 (67) | 6 (46) | |
  >40 Gy2 | 17 (40) | 10 (33) | 7 (54) | |
EGFR TKI during RT | 0.324 | |||
  No | 24 (56) | 15 (50) | 9 (69) | |
  Yes | 19 (44) | 15 (50) | 4 (31) | |
Type of EGFR TKI | 1.000 | |||
  Gefitinib | 5 (26) | 4 (27) | 1 (25) | |
  Erlotinib | 14 (74) | 11 (73) | 3 (75) | |
Chemotherapy during RT | 1.000 | |||
  No | 33 (77) | 23 (77) | 10 (77) | |
  Yes | 10 (23) | 7 (23) | 3 (23) | |